STAT+: In a sweeping executive order, Biden endorses importing drugs from Canada and orders a bigger drug pricing plan by late August
WASHINGTON — President Biden on Friday will take aim at the pharmaceutical industry by ordering…
Category: drug pricing
STAT+: House Democrats say pharma stock buybacks and dividends exceed R&D spending
A Congressional committee released a report on Thursday showing the 14 largest drug makers spent…
STAT+: Doctors Without Borders urges Roche to cut price of drug now recommended for Covid-19
After the World Health Organization recommended a Roche (RHHBY) drug to treat severe Covid-19, Doctors…
Are pharma mergers bad for biotech?
You’re reading the web edition of D.C. Diagnosis, STAT’s weekly newsletter about the politics and…
STAT+: Is the Alzheimer’s Association really pushing Biogen to lower its new drug’s price — or is it lip service?
WASHINGTON — The Alzheimer’s Association stunned Washington last month when it urged Biogen to lower…
STAT+: U.S. cancer drug prices were higher at launch than in three European countries — and just kept climbing
In the latest bid to compare drug costs, a new study finds that prices for…
STAT+: Revised analysis nudges up cost-effective price for Biogen’s Alzheimer’s drug to $3,000 to $8,400 a year
The controversial new Alzheimer’s drug from Biogen (BIIB) would be cost-effective only if priced between…
STAT+: ‘This is not enough’: Walmart’s plan to sell another private label insulin is met with skepticism
Amid a national outcry over the cost of insulin, Walmart (WMT) plans to sell a…
Opinion: Biden won’t end cancer — or any other disease — by importing drug price controls from Europe
In his first budget, President Biden set aggressive health goals. “Let’s end cancer as we…
Will Biogen’s new Alzheimer’s drug’s burden on Medicare be big, huge, or catastrophic?
The Food and Drug Administration’s decision to grant wide-ranging approval to the controversial, pricey new…
STAT+: In an about-face, Health Canada allows a controversial rare disease drug back on the market
In yet another twist in a complicated tale, Health Canada has reinstated approval of a…
STAT+: House leaders to investigate FDA approval and price of Biogen’s Alzheimer’s drug
WASHINGTON — The top House Democrats on two powerful committees on Friday announced an investigation…
STAT+: As Covid-19 rages in India, Gilead faces pressure to lower price of drug to treat rare infection
Over the past few months, thousands of people in India who survived Covid-19 returned to…
STAT+: Will FDA quickly review a Lilly drug to alleviate cost concerns for Alzheimer’s drugs?
In an unexpected move, U.S regulators granted Eli Lilly (LLY) a breakthrough designation for its…
STAT+: Pharmalittle: Inside the FDA’s contentious Aduhelm approval; Peter Bach heading to liquid biopsy startup
Good morning! Elizabeth Cooney here, sitting in for Ed Silverman, who would no doubt be…
STAT+: Teva to pay $925,000 to Mississippi to settle generic price-fixing charges
After years of controversy, Teva Pharmaceuticals (TEVA) agreed to pay $925,000 to the state of…
STAT+: Powerful Democrat’s new drug pricing manifesto hints at a carveout for small biotechs
WASHINGTON — Sen. Ron Wyden (D-Ore.), the influential chair of the Senate Finance Committee, is…
STAT+: Cost-effectiveness studies for widely used Medicare Part D drugs are few and far between
As more emphasis is placed on the value of prescription medicines, a new study found…
STAT+: BIO’s chief on the FDA commissioner rumors, drug pricing, and IP rights
WASHINGTON — Everyone wants to know whether Michelle McMurry-Heath, the newly minted president of the…
.jpg)
STAT+: HHS withdraws 340B drug discount opinion amid lawsuits by pharma companies
After a defeat in federal court, the Department of Health and Human Services withdrew an…
STAT+: A California law that bans drug coupons failed to increase generic use
A California law that banned coupons for brand-name prescription drugs failed to significantly boost greater…
STAT+: Poll: Many Americans concerned about FDA approval process for Alzheimer’s drug
Two-thirds of Americans who are familiar with the details of the newly approved Alzheimer’s treatment…
STAT+: Centene to pay $143 million to two states to settle allegations of overcharging Medicaid
Centene (CNC), a major health insurer, agreed to pay a combined $143 million to Ohio…
STAT+: Biden administration moves to axe Trump 340B rule targeting community clinics
WASHINGTON — The Biden administration on Tuesday moved to axe a Trump-era policy that would…
STAT+: Mississippi becomes the first state to jointly sue drug makers and PBMs over the cost of insulin
In a first-of-its-kind move, the Mississippi attorney general last week filed a lawsuit accusing several…
STAT+: ‘Simply unacceptable’: Alzheimer’s Association blasts Biogen over the price of its new medicine
In harsh tones, the Alzheimer’s Association sharply criticized Biogen (BIIB) for the $56,000 price tag…
Opinion: Unaffordable treatment for severe malaria highlights U.S. drug market pitfalls
When Eli Lilly announced in 2017 that it would stop producing quinidine, it was the…
STAT+: What’s next for the new Alzheimer’s drug? Lots of thorny issues ahead
Despite all the excitement surrounding the FDA’s approval on Monday of a controversial treatment for Alzheimer’s disease, the…
More than two-thirds of Congress cashed a pharma campaign check in 2020, new STAT analysis shows
WASHINGTON — Seventy-two senators and 302 members of the House of Representatives cashed a check…
Pharma funded more than 2,400 state lawmaker campaigns in 2020, new STAT analysis finds
WASHINGTON — State lawmakers in Oregon have tried to lower high drug prices from nearly…
STAT+: Despite its high price tag, the new Alzheimer’s drug isn’t reigniting the drug pricing debate
WASHINGTON — It has all the makings of a bombastic drug pricing debate: a highly…
STAT+: ‘The price is bewildering’:The price of Biogen’s Alzheimer’s drug may lead payers to erect roadblocks
The Food and Drug Administration’s approval on Monday of an Alzheimer’s drug developed by Biogen…
STAT+: Senate finance chair investigates AbbVie over its corporate tax strategy
AbbVie, which is already being probed by congressional Democrats for its pricing practices, is now…
STAT+: The parents hoped an existing drug might keep their kids from having seizures. Then they saw the price
When Amber Freed heard in 2020 that a drug might help save her young child…
STAT+: FTC issues a non-committal report on ‘rebate walls,’ but will the agency dig deeper?
In response to Congressional concerns over prescription drug pricing, the Federal Trade Commission released a…
STAT+: Pharmalittle: Biden in no rush to allow drug imports from Canada; deal on Covid-19 IP waiver remains elusive
Hello, everyone, and nice to see you again after taking an extended weekend break. Nothing…
STAT+: FDA revives a controversial program the Trump administration ended over ‘inaccuracies’
In an unexpected move, the Food and Drug Administration is reversing a decision by the…
.jpg)
STAT+: Drug makers argue an HHS rule would penalize them for offering co-pay coupons
After months of controversy, the pharmaceutical industry’s biggest trade group has filed a lawsuit accusing…
STAT+: Fewer state Medicaid programs are restricting access to hepatitis C medicines, but hurdles remain
Over the past few years, state Medicaid programs have done a better job of disclosing…
STAT+: Democrats call on FTC to investigate AbbVie’s Humira pricing strategy
WASHINGTON — Three powerful Democrats wrote to the Federal Trade Commission Tuesday urging them to…
STAT+: Congress is ready to grill AbbVie’s CEO over drug pricing
WASHINGTON — AbbVie CEO Richard Gonzalez is in for a congressional tongue-lashing of outsized proportion….
STAT+: Feds tell drug makers to offer discounts to safety-net hospitals or face penalties
After a year of controversy, the Health Resources and Services Administration notified six large drug…
STAT+: Brazil’s Supreme Court rules that patent extension rules are unconstitutional
The Brazilian Supreme Court ruled that a provision in the country’s intellectual property law allowing…
STAT+: ‘More Amazon and less pharmacy’: one exec on the company’s strategy for prescription drugs
Amazon’s objectives for its nascent pharmacy business are straightforward: “better selection, better convenience, and better…
STAT+: Key House Democrats’ push for a ‘bipartisan’ drug pricing bill could doom Pelosi’s signature legislation
WASHINGTON — A group of 10 moderate Democrats is urging House Speaker Nancy Pelosi to…
STAT+: Dutch advisory group says Zolgensma shouldn’t be covered unless Novartis halves price
In a challenge to Novartis (NVS), a Dutch advisory body has recommended that the government…
Opinion: Rather than turning its back on the QALY, pharma should collaborate on efforts to improve it
A key element in the long-simmering debate on reining in drug prices in the United…
STAT+: Incyte pays $12.6 million to resolve claims it paid drug kickbacks through charity
Incyte (INCY) agreed to pay $12.6 million to settle allegations that donations amounted to kickbacks…
STAT+: Pharma showers Menendez with rare, off-cycle burst of campaign cash as Democrats eye drug pricing reforms
WASHINGTON — Sen. Bob Menendez doesn’t face reelection until 2024, but pharmaceutical executives are already…
STAT+: Rising wholesale drug prices really do matter to half of all commercially insured Americans
Although the pharmaceutical industry argues that wholesale prices do not accurately reflect prescription drug costs,…